Novartis drug Zykadia gets positive trial results

ZURICH (Reuters) – Novartis cancer drug Zykadia showed positive results in a phase III clinical trial in treating patients with a form of lung cancer, the Swiss drugmaker said on Friday. Zykadia, whose generic name is ceritinib, displayed significant improvement in progression-free survival compared to standard chemotherapy in previously untreated patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer, it said. …

Originally posted here: 
Novartis drug Zykadia gets positive trial results